Opioid-Induced Constipation Market to Witness Growth by 2032, Estimates DelveInsight | AstraZeneca, Bausch Health, Cosmo pharmaceuticals, Daiichi Sankyo, Ironwood Pharmaceuticals Inc., Mallinckrodt
(Las Vegas, Nevada, USA) DelveInsight’s “Opioid-Induced Constipation Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Opioid-Induced Constipation, historical and forecasted epidemiology as well as the Opioid-Induced Constipation market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Opioid-Induced Constipation market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Opioid-Induced Constipation market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Opioid-Induced Constipation treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Opioid-Induced Constipation market.
Request for a Free Sample Report @ Opioid-Induced Constipation Market Forecast
Some facts of the Opioid-Induced Constipation Market Report are:
- According to DelveInsight, Opioid-Induced Constipation market size is expected to grow at a decent CAGR by 2032.
- Leading Opioid-Induced Constipation companies working in the market are AstraZeneca Plc, Bausch Health Companies Inc., Cosmo pharmaceuticals, Daiichi Sankyo, Ironwood Pharmaceuticals Inc., Mallinckrodt, Merck & Co. Inc., Novartis AG, Pfizer Inc., SHIONOGI Co. Ltd., Takeda Pharmaceutical, and others.
- Key Opioid-Induced Constipation Therapies expected to launch in the market are Mu-opioid Receptor Antagonists, Chloride Channel-2 Activators, and Others.
Opioid-Induced Constipation Overview
Opioid-induced constipation (OIC) is the most common side effect of opioid therapy because of the distribution of opioid receptors throughout the GI tract. Although OTC treatment for OIC is common, patients with more-severe symptoms often move to prescription drug therapy. The OIC drug market includes FDA-approved mu opioid receptor antagonists: Shionogi’s Symproic, Salix’s Relistor, and AstraZeneca / Daiichi Sankyo’s Movantik. Other therapies with alternative MOAs approved or in late-phase development include Allergan / Ironwood’s Linzess, a guanylate cyclase-C agonist; Mallinckrodt’s Amitiza, a bicyclic fatty acid; and Takeda’s Motegrity, a 5-HT4-receptor agonist. Given the number of agents now available / in development for OIC, understanding how and where each is positioned in the treatment algorithm is increasingly important as developers work to differentiate their product from the competition.
Learn more about Opioid-Induced Constipation treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/opioid-induced-constipation-market
Opioid-Induced Constipation Market
The Opioid-Induced Constipation market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Opioid-Induced Constipation market trends by analyzing the impact of current Opioid-Induced Constipation therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Opioid-Induced Constipation market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Opioid-Induced Constipation market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Opioid-Induced Constipation market in 7MM is expected to witness a major change in the study period 2019-2032.
Opioid-Induced Constipation Epidemiology
The Opioid-Induced Constipation epidemiology section provides insights into the historical and current Opioid-Induced Constipation patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Opioid-Induced Constipation market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Opioid-Induced Constipation Epidemiology @ https://www.delveinsight.com/sample-request/opioid-induced-constipation-market
Opioid-Induced Constipation Drugs Uptake
This section focuses on the uptake rate of the potential Opioid-Induced Constipation drugs recently launched in the Opioid-Induced Constipation market or expected to be launched in 2019-2032. The analysis covers the Opioid-Induced Constipation market uptake by drugs, patient uptake by therapies, and sales of each drug.
Opioid-Induced Constipation Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Opioid-Induced Constipation market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Opioid-Induced Constipation Pipeline Development Activities
The Opioid-Induced Constipation report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Opioid-Induced Constipation key players involved in developing targeted therapeutics.
Request for a sample report to understand more about the Opioid-Induced Constipation pipeline development activities @ https://www.delveinsight.com/sample-request/opioid-induced-constipation-market
Opioid-Induced Constipation Therapeutics Assessment
Major key companies are working proactively in the Opioid-Induced Constipation Therapeutics market to develop novel therapies which will drive the Opioid-Induced Constipation treatment markets in the upcoming years are AstraZeneca Plc, Bausch Health Companies Inc., Daiichi Sankyo, Ironwood Pharmaceuticals Inc., Mallinckrodt, Merck & Co. Inc., Novartis AG, Pfizer Inc., SHIONOGI Co. Ltd., Takeda Pharmaceutical, and others.
Learn more about the emerging Opioid-Induced Constipation therapies & key companies @ https://www.delveinsight.com/sample-request/opioid-induced-constipation-market
Opioid-Induced Constipation Report Key Insights
1. Opioid-Induced Constipation Patient Population
2. Opioid-Induced Constipation Market Size and Trends
3. Key Cross Competition in the Opioid-Induced Constipation Market
4. Opioid-Induced Constipation Market Dynamics (Key Drivers and Barriers)
5. Opioid-Induced Constipation Market Opportunities
6. Opioid-Induced Constipation Therapeutic Approaches
7. Opioid-Induced Constipation Pipeline Analysis
8. Opioid-Induced Constipation Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Opioid-Induced Constipation Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Opioid-Induced Constipation Competitive Intelligence Analysis
4. Opioid-Induced Constipation Market Overview at a Glance
5. Opioid-Induced Constipation Disease Background and Overview
6. Opioid-Induced Constipation Patient Journey
7. Opioid-Induced Constipation Epidemiology and Patient Population
8. Opioid-Induced Constipation Treatment Algorithm, Current Treatment, and Medical Practices
9. Opioid-Induced Constipation Unmet Needs
10. Key Endpoints of Opioid-Induced Constipation Treatment
11. Opioid-Induced Constipation Marketed Products
12. Opioid-Induced Constipation Emerging Therapies
13. Opioid-Induced Constipation Seven Major Market Analysis
14. Attribute Analysis
15. Opioid-Induced Constipation Market Outlook (7 major markets)
16. Opioid-Induced Constipation Access and Reimbursement Overview
17. KOL Views on the Opioid-Induced Constipation Market
18. Opioid-Induced Constipation Market Drivers
19. Opioid-Induced Constipation Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting-services